Manager × security

venBio Partners LLC ALXO holdings history

ALX ONCOLOGY HOLDINGS INC · CUSIP 00166B105 · CIK 1776382

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, venBio Partners LLC reported 12.88M ALXO (shares), valued at $26.67M, or 5.14% of its reported non-derivative portfolio. Filed 2026-08-14.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
5.14%
Shares
12.88M
12,884,638
Reported value
$26.67M
USD

Shares unchanged; reported value increased 3.24%, and weight changed -4.07 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20265.14%12,884,638SEC filing ↗Filed Aug 14, 2026
Q1 20269.21%12,884,638SEC filing ↗Filed May 15, 2026
Q4 20255.07%9,699,925SEC filing ↗Filed Feb 17, 2026
Q3 202510.06%9,699,925SEC filing ↗Filed Nov 14, 2025
Q2 20253.51%9,699,925SEC filing ↗Filed Aug 14, 2025
Q1 20254.89%9,699,925SEC filing ↗Filed May 15, 2025
Q4 20249.49%9,699,925SEC filing ↗Filed Feb 14, 2025
Q3 20249.08%9,699,925SEC filing ↗Filed Nov 14, 2024
Q2 202425.26%9,699,925SEC filing ↗Filed Aug 14, 2024
Q1 202438.37%9,699,925SEC filing ↗Filed May 15, 2024
Q4 202321.65%9,699,925SEC filing ↗Filed Feb 14, 2024
Q3 202313.20%9,699,925SEC filing ↗Filed Nov 14, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 202313.20%9,699,925$46.56MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Nov 14, 2023
Q4 202321.65%9,699,925$144.43MShares unchanged; reported value increased 210.21%, and weight changed +8.45 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2024
Q1 202438.37%9,699,925$108.15MShares unchanged; reported value decreased 25.12%, and weight changed +16.72 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2024
Q2 202425.26%9,699,925$58.49MShares unchanged; reported value decreased 45.92%, and weight changed -13.11 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2024
Q3 20249.08%9,699,925$17.65MShares unchanged; reported value decreased 69.82%, and weight changed -16.18 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2024
Q4 20249.49%9,699,925$16.20MShares unchanged; reported value decreased 8.24%, and weight changed +0.41 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2025
Q1 20254.89%9,699,925$6.04MShares unchanged; reported value decreased 62.69%, and weight changed -4.60 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2025
Q2 20253.51%9,699,925$4.03MShares unchanged; reported value decreased 33.37%, and weight changed -1.38 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2025
Q3 202510.06%9,699,925$17.75MShares unchanged; reported value increased 340.86%, and weight changed +6.55 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2025
Q4 20255.07%9,699,925$10.96MShares unchanged; reported value decreased 38.25%, and weight changed -4.99 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 17, 2026
Q1 20269.21%12,884,638$25.83MShares increased 32.83%; reported value increased 135.69%, and weight changed +4.14 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2026
Q2 20265.14%12,884,638$26.67MShares unchanged; reported value increased 3.24%, and weight changed -4.07 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2026
venBio Partners LLC · ALX ONCOLOGY HOLDINGS INC

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1776382","quarter":"2026Q2","cusip":"00166B105"}

get_institutional_manager_history
{"cik":"1776382","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.